TIRZEPATIDE
information
What is Tirzepatide?
Tirzepatide, or LY3298176, is a unimolecular dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is under study for its glycemic control and weight loss benefits
Tirzepatide is based on the human GIP hormone and has a length of 39 amino acids. It includes a C20 fatty di-acid moiety that provides extended duration and allows for once-weekly dosing in humans
DOSE PROTOCOL
Based on the available information to date, here is a reference Tirzepatide dosing protocol to induce weight loss in obese or overweight subjects:
*Starting Dose (Weeks 1-4): 2.5mg/week for the first four weeks of the study period.
*Dose Increase (Weeks 5-24): Increase total weekly dose to 5mg.
*Evaluate response and further increase the total weekly dose
in 2.5/mg increments, as needed.
Frequency: Once per week, subcutaneous.
Duration: 12-24 weeks.
Notes: The maximum established weekly dose is 15mg, per the Mounjaro dosing guidelines and clinical trial data.